Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

11160	Companies
246377	Keywords
174358	Articles
133067	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 10/30/2025 at 22:59, 11 months 13 days ago

Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Biophytis reports financial results for the first half of 2025, strategic update, and key achievements in sarcopenia and obesity. Plans for Phase 2 and Phase 3 studies outlined with focus on sustaining growth and value creation

Financial Results Biophytis Sarcopenia Strategic Update Obesity
BRIEF

published on 10/13/2025 at 07:05, 11 months 30 days ago

Biophytis and Asian Investors to Launch Phase 3 Sarcopenia Trial

Biophytis Phase 3 Trial Sarcopenia BIO101 Asian Investors
REGULATED PRESS RELEASE

published on 10/13/2025 at 07:00, 11 months 30 days ago

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia
BIOPHYTIS and a Consortium of Investors partner to finance and launch Phase 3 Trial in Sarcopenia, creating a joint venture in Hong Kong with US$20 million investment for clinical operations starting early 2026

Biophytis Joint Venture Phase 3 Trial Sarcopenia Consortium Of Investors
BRIEF

published on 09/30/2025 at 07:05, 1 year ago

Biophytis to Engage in Key Events in Q4 2025

Biophytis Partnerships Longevity Sarcopenia Biotechnology Events
REGULATED PRESS RELEASE

published on 09/30/2025 at 07:00, 1 year ago

Biophytis to Participate in Four Key Events in Q4 2025
Biophytis to participate in four major international events in Q4 2025, showcasing its progress in transformative therapies impacting longevity and seeking new partnerships

Biophytis Partnerships Longevity International Events Transformative Therapies
BRIEF

published on 09/15/2025 at 07:05, 1 year ago

Biophytis Secures Funding for Obesity Trial in Brazil

Biophytis Brazil Obesity Trial EMBRAPII Clinical Partnerships
REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 1 year ago

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII

Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
BRIEF

published on 09/11/2025 at 07:05, 1 year 1 month ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 1 year 1 month ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 1 year 1 month ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization

Accesswire

Published on 10/12/2026 at 22:01, 3 hours 12 minutes ago

Fermi Announces Third Quarter 2026 Earnings Release and Call Date
Published on 10/12/2026 at 15:00, 10 hours 13 minutes ago

Shelfie-Tech Announces Closing of Private Placement
Published on 10/12/2026 at 13:00, 12 hours 13 minutes ago

U.S. Energy Secretary Chris Wright, EXIM Chairman John Jovanovic, Nebraska Governor Jim Pillen, Senators Deb Fischer and Pete Ricketts, and Congressman Adrian Smith to Visit NioCorp's Critical Minerals Mine Site
Published on 10/10/2026 at 04:45, 2 days 20 hours ago

Immutable Holdings and Jorge Masvidal's Gamebred Fighting Championship (FC) Enter Into Definitive Agreement for Proposed Reverse Takeover Transaction and Listing on the TSXV
Published on 10/10/2026 at 02:03, 2 days 23 hours ago

BrandPilot AI Announces Closing of Previously Announced Debt Settlement

View all ACCESSWIRE

EQS Group

Published on 10/12/2026 at 20:30, 4 hours 43 minutes ago

Correction of a release from 29.09.2026 18:15 CET/CEST - Multi Units Luxembourg: NOTICE TO THE SHAREHOLDERS
Published on 10/12/2026 at 20:30, 4 hours 43 minutes ago

Correction of a release from 02.10.2026 14:59 CET/CEST - Multi Units Luxembourg: NOTICE TO THE SHAREHOLDERS
Published on 10/12/2026 at 20:05, 5 hours 8 minutes ago

SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
Published on 10/12/2026 at 19:10, 6 hours 3 minutes ago

Cell Impact announces acceleration of previously communicated order from US customer
Published on 10/12/2026 at 18:45, 6 hours 28 minutes ago

Fraikin announces exclusive agreement with Asterion Industrial Partners to support its next phase of growth

Les Echos

Published on 10/12/2026 at 17:59, 7 hours 14 minutes ago

Reporting on share buyback transactions carried out between October 7 and October 9, 2026
Published on 10/12/2026 at 17:45, 7 hours 28 minutes ago

Weekly share buyback
Published on 10/12/2026 at 17:45, 7 hours 28 minutes ago

Declaration of transactions on own shares from October 5, 2026 to October 11, 2026
Published on 10/12/2026 at 15:47, 9 hours 26 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of September 30, 2026
Published on 10/12/2026 at 15:12, 10 hours 1 minute ago

Statement of transactions in own shares from October 5, 2026 to October 9, 2026

View all LES ECHOS COMFI WIRE